Lichen sclerosus
Chronic inflammatory dermatosis of the anogenital region — vulvar in women, foreskin/glans in men (balanitis xerotica obliterans, BXO), with pediatric (~7-15% of vulvar LS) and postmenopausal peaks — managed lifelong with ultrapotent topical corticosteroids and annual surveillance for squamous cell carcinoma. Features: porcelain-white atrophic plaques + pruritus + soreness + dyspareunia + architectural changes (labial fusion, clitoral hood phimosis, introital stenosis, foreskin phimosis); 'figure-8' or 'hourglass' perianal-vulvar pattern; subepithelial hemorrhage and ecchymosis-like lesions. CRITICAL SAFETY: 4-5% lifetime VULVAR squamous cell carcinoma (SCC) risk in untreated LS; 2-12% in inadequately treated; ANNUAL EXAM SURVEILLANCE LOAD-BEARING; differentiated VIN (dVIN) precursor lesion. Standard of care: ULTRAPOTENT TOPICAL CORTICOSTEROIDS — clobetasol propionate 0.05% ointment — nightly induction 4-12 weeks then maintenance 2-3x/week LIFELONG; reduces SCC risk. Pimecrolimus + tacrolimus calcineurin inhibitors steroid-sparing. Topical estrogen if coexisting menopausal atrophy (GSM). Surgery (adhesion lysis, circumcision for severe phimosis) for established architectural change. British Association of Dermatologists 2018 + AAD + ISSVD. Pediatric LS overlaps visually with sexual abuse findings — pediatric dermatology + child-protective evaluation pathways navigated simultaneously. Fortieth deliberate non-elevation.
What changes during this transition
Lichen sclerosus is underdiagnosed, under-discussed, and load-bearingly under-respected as a condition. Vulvar LS in particular sits at the intersection of three things that delay care: anogenital symptoms patients don't bring up, primary-care clinicians who haven't seen it recently enough to recognize the porcelain-white plaques, and a postmenopausal demographic that gets told 'this is just atrophy' for years before someone biopsies. Penile LS (balanitis xerotica obliterans, BXO) follows the same arc — phimosis attributed to hygiene or aging before the dermatosis is recognized. Pediatric vulvar LS — roughly 7-15% of vulvar LS cases — is its own editorial minefield because the bruising, subepithelial hemorrhage, and architectural changes overlap visually with sexual abuse findings; pediatric dermatology and child-protective evaluation pathways have to be navigated carefully and simultaneously. The standard of care is well-established and load-bearing: ultrapotent topical corticosteroids — clobetasol propionate 0.05% ointment — nightly during induction (typically 4-12 weeks) and then 2-3x/week maintenance FOR LIFE. The 'for life' part is non-negotiable and frequently undermined by clinicians who, out of steroid-atrophy concern, taper patients off and then watch them relapse. The lifetime vulvar squamous cell carcinoma (SCC) risk in untreated or inadequately treated LS is 4-5% — and a substantial body of evidence shows that adherent topical-steroid maintenance reduces that risk. Annual surveillance examination by a clinician who knows what differentiated VIN (dVIN) looks like is load-bearing. Pediatric LS doesn't carry the same SCC risk profile but does carry maintenance-treatment requirements and pediatric-dermatology follow-up. Second-line options — pimecrolimus and tacrolimus calcineurin inhibitors (steroid-sparing, less effective, black-box warning that the dermatology literature largely considers overcautious for short-term anogenital use), topical estrogen for menopausal atrophy overlap, surgery for adhesion lysis and severe phimosis (circumcision is curative for many cases of penile LS), and emerging modalities including fractional CO2 laser, photodynamic therapy, platelet-rich plasma (PRP), and adipose-derived stem cell injections — exist but none displace clobetasol as first-line. Methotrexate and acitretin sit in the refractory tier. The British Association of Dermatologists 2018 guidelines and AAD/ISSVD positions converge on this framework. The peptide-community framing for lichen sclerosus is exactly where editorial discipline has to bite hardest. BPC-157 and TB-500 get pitched for 'skin healing' and 'tissue regeneration'; KPV gets the α-MSH-derivative mucocutaneous anti-inflammatory framing; LL-37 gets framed for chronic inflammatory skin conditions; and various longevity-adjacent peptides get pulled into 'atrophy reversal' conversations that misread vulvar architectural change as a hormonal-aging problem rather than an immune-mediated inflammatory dermatosis. None of these peptides has lichen sclerosus trial data. The mechanism stories range from logically adjacent (KPV, in the abstract) to actively contraindicated (LL-37, which sits on the wrong side of the autoimmune-dysregulation thread that LS shares with morphea and other immune-mediated dermatoses). The honest answer at /ask is the same across all of them: clobetasol is first-line, lifelong, with annual surveillance — and a peptide protocol that substitutes for or undermines that is a patient-safety problem, not a peptide problem.
Important caveat
Lichen sclerosus is a condition that requires lifelong topical-corticosteroid maintenance and annual surveillance examination by a clinician familiar with vulvar/penile dermatology — typically a dermatologist, vulvar-specialty gynecologist, or urologist depending on anatomy. A 4-5% LIFETIME VULVAR SCC RISK in untreated or inadequately treated disease is the load-bearing safety fact. CLOBETASOL PROPIONATE 0.05% OINTMENT — nightly induction 4-12 weeks then 2-3x/week LIFELONG MAINTENANCE — is first-line; abrupt discontinuation is associated with relapse and elevated SCC risk and should not happen without dermatologist coordination. ANNUAL SURVEILLANCE EXAMINATION load-bearing — looking for porcelain-white plaques, architectural change progression, and any focal thickening, ulceration, or hyperkeratosis suspicious for differentiated VIN or invasive SCC. Biopsy any atypical or refractory area. No peptide currently on the community radar has lichen sclerosus trial evidence; none should be considered as a substitute for clobetasol. Pediatric lichen sclerosus requires pediatric-dermatology evaluation and should not be confused with — or evaluated separately from — child-protective concerns; both pathways may need to run simultaneously, with attention to the visual overlap between LS bruising/bleeding/architectural change and abuse findings. Differential diagnosis includes lichen planus, vitiligo, extramammary Paget's disease, Behçet's, and the autoimmune blistering diseases (EBA, MMP). Postmenopausal vulvar symptoms should not be dismissed as 'just atrophy' without close examination and biopsy of anything atypical — LS and GSM (genitourinary syndrome of menopause) can coexist and have different treatments (corticosteroid vs estrogen). Topical estrogen is appropriate alongside clobetasol when GSM overlaps. LL-37 specifically carries autoimmune-amplification concern via the psoriasis-pDC-interferon literature — directionally wrong in immune-mediated dermatosis with autoimmune comorbidity clustering. WADA athletes: BPC-157 (S0) and TB-500 (S2) prohibited at all times. Pregnancy: LS continues during pregnancy; clobetasol continued (topical steroids generally pregnancy-compatible with low-dose anogenital application); perineal trauma at delivery is a concern for vulvar LS — coordinate with dermatologist + maternal-fetal medicine + delivering OB. Lichen Sclerosus Support Network + Vulval Pain Society are patient-organization resources.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.